Search Results

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice.

• Authors : Modder M; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

Subjects: Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/genetics ; Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/Angiopoietin-Like Protein 4*/metabolism ; Atherosclerosis*/Atherosclerosis*/Atherosclerosis*/genetics

• Source: Cardiovascular research [Cardiovasc Res] 2024 Dec 31; Vol. 120 (17), pp. 2179-2190.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245

Record details

CETP inhibition and HDL: what is the trial REVEALing?

• Authors : Badimon L; Cardiovascular Science Institute - ICCC, IIB-Sant Pau, CIBERCV, Barcelona, Spain.; Cardiovascular Research Chair UAB (Autonomous University of Barcelona), Barcelona, Spain.

Subjects: Atherosclerosis* ; Cholesterol Ester Transfer Proteins*; Humans

• Source: Cardiovascular research [Cardiovasc Res] 2018 Feb 01; Vol. 114 (2), pp. e15-e16.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245

Record details

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

• Authors : Tchoua U; Baker Heart Research Institute, Melbourne, Victoria, Australia.; D'Souza W

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacology ; Cholesterol/Cholesterol/Cholesterol/*metabolism ; Cholesterol Ester Transfer Proteins/Cholesterol Ester Transfer Proteins/Cholesterol Ester Transfer Proteins/*antagonists & inhibitors

• Source: Cardiovascular research [Cardiovasc Res] 2008 Mar 01; Vol. 77 (4), pp. 732-9. Date of Electronic Publication: 2007 Dec 04.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print-Electronic Cited Medium: Print ISSN:

Record details

High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.

• Authors : Levy Y

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*adverse effects ; Cholesterol Ester Transfer Proteins/Cholesterol Ester Transfer Proteins/Cholesterol Ester Transfer Proteins/*antagonists & inhibitors ; Cholesterol, HDL/Cholesterol, HDL/Cholesterol, HDL/*metabolism

• Source: Cardiovascular research [Cardiovasc Res] 2008 Mar 01; Vol. 77 (4), pp. 614-5. Date of Electronic Publication: 2008 Jan 10.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print-Electronic Cited Medium: Print ISSN:

Record details

HDL particles and infection-related death: when size matters.

• Authors : Calabresi, Laura¹ (AUTHOR); Norata, Giuseppe Danilo¹ (AUTHOR)

Subjects: *CHOLESTERYL ester transfer protein; *LIPID transfer protein; *ACUTE phase proteins

• Source: Cardiovascular Research. Apr2023, Vol. 119 Issue 4, p883-885. 3p.

Record details

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

Subjects: *CHOLESTERYL ester transfer protein; *LDL cholesterol; *HDL cholesterol

• Source: Cardiovascular Research. Oct2022, Vol. 118 Issue 14, p2919-2931. 13p.

Record details

Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis.

• Authors : Galle-Treger, Lauriane¹ (AUTHOR); Moreau, Martine¹ (AUTHOR); Ballaire, Raphaëlle¹ (AUTHOR)

Subjects: *CHOLESTERYL ester transfer protein; *WESTERN diet; *MACROPHAGES

• Source: Cardiovascular Research. Mar2020, Vol. 116 Issue 3, p554-565. 12p.

Record details

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

• Authors : Nurmohamed NS; Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.; Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 HV, Amsterdam, TheNetherlands.

Subjects: Cardiovascular Diseases* ; Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/adverse effects; Humans

• Source: Cardiovascular research [Cardiovasc Res] 2022 Nov 10; Vol. 118 (14), pp. 2919-2931.Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245

Record details

From lipid locus to drug target through human genomics.

• Authors : Laan, Sander W van der; Harshfield, Eric L; Hemerich, Daiane

Subjects: CORONARY heart disease risk factors; LIPIDS; GENOMICS

• Source: Cardiovascular Research; 7/15/2018, Vol. 114 Issue 9, p1258-1270, 13p

Record details

Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a).

• Authors : Trinder, Mark^1,2 (AUTHOR); Zekavat, Seyedeh Maryam^2,3 (AUTHOR); Uddin, Md Mesbah² (AUTHOR)

Subjects: *APOLIPOPROTEIN B; *CORONARY disease; *CHOLESTERYL ester transfer protein

• Source: Cardiovascular Research. May2021, Vol. 117 Issue 5, p1245-1247. 3p.

Record details